IBD Science for Patients

Living with Inflammatory Bowel Disease (IBD) is hard enough, but a new study suggests that your bank account and your address might play a bigger role in your treatment than you think. Researchers have been looking at biologics – powerful, advanced medicines that can help people reach remission – to see if everyone has the same chance of getting them.

What the Research Found

This was a large-scale national study conducted in Brazil, looking at data from the public healthcare system over a 14-year period (2008 to 2022). Because it was an “ecological study,” it analysed information from thousands of different municipalities (towns and cities) to see how socioeconomic conditions affect IBD care.

The good news is that the use of biologics is rising significantly. In 2008, only about 3% of IBD prescriptions in the public system were for biologics; by 2022, that number had jumped to nearly 17%.

However, the study also revealed some unfair gaps:

• The Inequality Gap: In areas where there was a big difference between the rich and the poor (income inequality), patients were 6% less likely to be prescribed biologic treatments.
• The Development Paradox: Curiously, in the wealthiest and most developed areas, biologic prescriptions through the public system were actually lower. Researchers believe this is because people in those areas are more likely to have private health insurance, so they get their medicine outside of the public system, making them “invisible” to public data.

Why This Matters to You as a Patient

Even if you don’t live in Brazil, this research highlights a global issue called Health Equity – the idea that everyone should have a fair chance to be as healthy as possible.

1. Advocating for Advanced Care: If you feel your IBD isn’t well-controlled, this study is a reminder to ask your doctor about all available options, including biologics. Don’t be afraid to ask if there are advanced treatments you might be eligible for.
2. Highlighting System Gaps: Studies like this help patient organisations fight for better rules. They prove that doctors need to look beyond just the “biology” of the disease and consider the “barriers” (like cost or location) that might stop a patient from getting the best care.
3. The Importance of Data: The researchers noted that because public and private systems don’t always share data, it’s hard to see the full picture of IBD care. As a patient, keeping your own clear records of your treatments can help ensure your next doctor has the full story, no matter where you live.

Ultimately, your health should depend on your medical needs, not your postcode.

Explore the Research

• Original Article: Association Between Socioeconomic Conditions and Biologic Prescriptions for IBD.
• UK Quality Standards: 2026 IBD UK Standards for healthcare service design.
• Global Equity Research: Equity gaps are now a frontline issue in IBD care.